Abstract Book - PDF - San Antonio Breast Cancer Symposium
18.06.2014 • Views
Share Embed Flag

Abstract Book - PDF - San Antonio Breast Cancer Symposium

Abstract Book - PDF - San Antonio Breast Cancer Symposium

Abstract Book - PDF - San Antonio Breast Cancer Symposium

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
sabcs.org

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

CTRC-AACR <strong>San</strong> <strong>Antonio</strong> <strong>Breast</strong> <strong>Cancer</strong> <strong>Symposium</strong><br />

Biology of Triple-Negative <strong>Breast</strong> <strong>Cancer</strong><br />

Ballroom B<br />

Moderator: Nicholas Turner, MD<br />

Royal Marsden Hospital<br />

London, UNITED KINGDOM<br />

New vulnerabilities for TNBC – from genetics to<br />

therapeutics<br />

Thomas Westbrook, PhD<br />

Baylor College of Medicine<br />

Houston, TX<br />

Triple negative breast cancer: Subtypes, molecular targets,<br />

and therapeutic approaches<br />

Jennifer A. Pietenpol, PhD<br />

Vanderbilt University School of Medicine<br />

Nashville, TN<br />

The clonal and mutational evolution of primary triple<br />

negative breast cancers<br />

Samuel Aparicio, PhD<br />

University of British Columbia<br />

Vancouver, CANADA<br />

Clinical Trial Designs for New Therapies<br />

Exhibit Hall D<br />

Moderator: Susan G. Hilsenbeck, PhD<br />

Baylor College of Medicine<br />

Houston, TX<br />

Early phase trials - What are they for?<br />

Susan G. Hilsenbeck, PhD<br />

Baylor College of Medicine<br />

Houston, TX<br />

What agents should go into trials?<br />

Angela DeMichele, MD, MSCE<br />

University of Pennsylvania Perelman School of Medicine<br />

Philadelphia, PA<br />

What endpoints should we use?<br />

Clifford A. Hudis, MD<br />

Memorial Sloan-Kettering <strong>Cancer</strong> Center<br />

New York, NY<br />

Randomized clinical trial designs: Still important<br />

Sally Hunsberger, PhD<br />

National <strong>Cancer</strong> Institute<br />

Rockville, MD<br />

What have we learned?<br />

Susan G. Hilsenbeck, PhD<br />

Baylor College of Medicine<br />

Houston, TX<br />

4:00 pm–5:30 pm<br />

Navigating the Obstacles and Risks of Survivorship<br />

Ballroom A<br />

Moderator: Susan W. Rafte<br />

Pink Ribbons Project<br />

Houston, TX<br />

Emerging sexual pharmacology for the breast cancer<br />

survivor<br />

Michael Krychman, MD<br />

The Southern California Center for Sexual Health and Survivorship<br />

Newport Beach, CA<br />

Cognitive changes and breast cancer treatments<br />

Patricia A. Ganz, MD<br />

University of California, Los Angeles<br />

Los Angeles, CA<br />

Risk of second primary breast cancer and other serious late<br />

complications issues among survivors of breast cancer<br />

Jonine L. Bernstein, PhD<br />

Memorial Sloan-Kettering <strong>Cancer</strong> Center<br />

New York, NY<br />

Mammary Cell Lineages and <strong>Breast</strong> <strong>Cancer</strong> Subtypes<br />

Ballroom B<br />

Moderator: Michael T. Lewis, PhD<br />

Baylor College of Medicine<br />

Houston, TX<br />

Primitive normal human mammary cells – the forerunners<br />

of malignant populations<br />

Connie Eaves, PhD<br />

University of British Columbia<br />

Vancouver, CANADA<br />

Deciphering the cellular hierarchy of the mammary gland<br />

and its implication for breast cancer<br />

Marielle Ousset, PhD<br />

Université Libre de Bruxelles<br />

Bruxelles, BELGIUM<br />

Understanding human cancer with single cell genetics<br />

Nicholas E. Navin, PhD<br />

UT MD Anderson <strong>Cancer</strong> Center<br />

Houston, TX<br />

Controversies in the Surgical Management of <strong>Breast</strong> <strong>Cancer</strong><br />

Exhibit Hall D<br />

Moderator: Ismail Jatoi, MD, PhD, FACS<br />

UT Health Science Center <strong>San</strong> <strong>Antonio</strong><br />

<strong>San</strong> <strong>Antonio</strong>, TX<br />

Sentinel node biopsy in breast cancer: Before or after<br />

neoadjuvant chemotherapy<br />

Eleftherios Mamounas, MD<br />

Aultman Hospital<br />

Canton, OH<br />

Evolving trends in implant breast reconstruction<br />

Andrea L. Pusic, MD, MHS, FRCSC<br />

Memorial Sloan-Kettering <strong>Cancer</strong> Center<br />

New York, NY<br />

The role of MRI in management of primary breast cancer<br />

Ismail Jatoi, MD, PhD, FACS<br />

UT Health Science Center <strong>San</strong> <strong>Antonio</strong><br />

<strong>San</strong> <strong>Antonio</strong>, TX<br />

6:00 pm–7:30 pm<br />

Tumor Dormancy and Late Recurrences<br />

Ballroom A<br />

Moderator: George W. Sledge, Jr, MD<br />

Indiana University Simon <strong>Cancer</strong> Center<br />

Indianapolis, IN<br />

Mechanisms of breast cancer dormancy and recurrence<br />

Lewis A. Chodosh, MD, PhD<br />

Perelman School of Medicine<br />

University of Pennsylvania<br />

Philadelphia, PA<br />

Tumor dormancy from an experimental biologist’s<br />

perspective<br />

Ann F. Chambers, PhD<br />

London Regional <strong>Cancer</strong> Program<br />

London, CANADA<br />

Attacking tumor dormancy in the clinic: How do we design<br />

the trials?<br />

George W. Sledge, Jr, MD<br />

Indiana University Simon <strong>Cancer</strong> Center<br />

Indianapolis, IN<br />

<strong>Cancer</strong> Res; 72(24 Suppl.) December 15, 2012 4s <strong>Cancer</strong> Research

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!